Literature DB >> 9820182

Immunohistochemical analysis of intratumoral heterogeneity of [131I]cG250 antibody uptake in primary renal cell carcinomas.

M G Steffens1, E Oosterwijk, N E Zegwaart-Hagemeier, M A van't Hof, F M Debruyne, F H Corstens, O C Boerman.   

Abstract

In previous studies, highly heterogeneous uptake of 131I-labelled chimeric monoclonal antibody G250 ([131I]cG250) in primary renal cell carcinomas has been observed (intratumoral differences > factor 100). In this study, we investigated a possible correlation between intratumoral antibody uptake and four immunohistochemically determined parameters: G250 antigen expression, blood vessel density, neovascularization and percentage of viable tumour cells. Whole tumour slices of four different tumours were cut into 1-cm3 cubes, and in each cube the [131I]cG250 uptake was determined. The correlation between [131I]cG250 uptake and each individual parameter was determined in a multiple regression analysis. Additionally, the data were reanalysed after introducing arbitrary cut-off values for each parameter. If a sample showed expression of a parameter above the introduced threshold value, this sample fulfilled one condition. Subsequently, the Pearson correlation coefficients were calculated from [131I]cG250 uptake and the number of fulfilled conditions (0-3). All tumour samples with high [131I]cG250 uptake [> 0.1% of the injected dose per gram (ID g(-1))] showed high antigen expression (> 50%). However, not all samples with high antigen expression displayed high uptake. A statistically significant correlation between [131I]cG250 uptake and antigen expression was found (beta = 0.44, 0.69 and 0.74) in three out of four tumours analysed. Of the other determined parameters, no consistent correlation with [131I]cG250 uptake was found; only the percentage of viable tumour cells correlated significantly in two out of four tumours (beta = 0.80 and 0.26). Calculation of the Pearson correlation coefficients showed a statistically significant correlation between [131I]cG250 uptake and an increased number of fulfilled conditions in all tumours, indicating that each of the individual parameters contribute to the uptake of [131I]cG250. These observations indicate that high antigen expression is a prerequisite for high antibody uptake. However, regional differences in antibody uptake within a tumour cannot be explained by antigen expression alone.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9820182      PMCID: PMC2063006          DOI: 10.1038/bjc.1998.656

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  18 in total

1.  A quantitative analysis of tumor specific monoclonal antibody uptake by human melanoma xenografts: effects of antibody immunological properties and tumor antigen expression levels.

Authors:  T R Shockley; K Lin; C Sung; J A Nagy; R G Tompkins; R L Dedrick; H F Dvorak; M L Yarmush
Journal:  Cancer Res       Date:  1992-01-15       Impact factor: 12.701

2.  Monoclonal antibody G 250 recognizes a determinant present in renal-cell carcinoma and absent from normal kidney.

Authors:  E Oosterwijk; D J Ruiter; P J Hoedemaeker; E K Pauwels; U Jonas; J Zwartendijk; S O Warnaar
Journal:  Int J Cancer       Date:  1986-10-15       Impact factor: 7.396

3.  Use of monoclonal antibodies to keratin 7 in the differential diagnosis of adenocarcinomas.

Authors:  F Ramaekers; C van Niekerk; L Poels; E Schaafsma; A Huijsmans; H Robben; G Schaart; P Vooijs
Journal:  Am J Pathol       Date:  1990-03       Impact factor: 4.307

Review 4.  Radioimmunotherapy: recent results and future directions.

Authors:  R B Wilder; G L DeNardo; S J DeNardo
Journal:  J Clin Oncol       Date:  1996-04       Impact factor: 44.544

5.  A modeling analysis of monoclonal antibody percolation through tumors: a binding-site barrier.

Authors:  K Fujimori; D G Covell; J E Fletcher; J N Weinstein
Journal:  J Nucl Med       Date:  1990-07       Impact factor: 10.057

6.  Antibody localization in human renal cell carcinoma: a phase I study of monoclonal antibody G250.

Authors:  E Oosterwijk; N H Bander; C R Divgi; S Welt; J C Wakka; R D Finn; E A Carswell; S M Larson; S O Warnaar; G J Fleuren
Journal:  J Clin Oncol       Date:  1993-04       Impact factor: 44.544

7.  Physiological factors influencing radioantibody uptake: a study of four human colonic carcinomas.

Authors:  R D Blumenthal; R M Sharkey; R Kashi; A M Natale; D M Goldenberg
Journal:  Int J Cancer       Date:  1992-07-30       Impact factor: 7.396

8.  Local hyperthermia and SR 4233 enhance the antitumor effects of radioimmunotherapy in nude mice with human colonic adenocarcinoma xenografts.

Authors:  R B Wilder; V K Langmuir; H L Mendonca; M L Goris; S J Knox
Journal:  Cancer Res       Date:  1993-07-01       Impact factor: 12.701

Review 9.  Platelet endothelial cell adhesion molecule (CD31).

Authors:  H M DeLisser; P J Newman; S M Albelda
Journal:  Curr Top Microbiol Immunol       Date:  1993       Impact factor: 4.291

10.  Tumor angiogenesis and interstitial hypertension.

Authors:  Y Boucher; M Leunig; R K Jain
Journal:  Cancer Res       Date:  1996-09-15       Impact factor: 12.701

View more
  3 in total

Review 1.  Application of monoclonal antibody G250 recognizing carbonic anhydrase IX in renal cell carcinoma.

Authors:  Jeannette C Oosterwijk-Wakka; Otto C Boerman; Peter F A Mulders; Egbert Oosterwijk
Journal:  Int J Mol Sci       Date:  2013-05-29       Impact factor: 5.923

2.  Quantitative intratumoural microdistribution and kinetics of (131)I-huA33 antibody in patients with colorectal carcinoma.

Authors:  Marika Ciprotti; Geoffrey Chong; Hui K Gan; Anthony Chan; Carmel Murone; Duncan MacGregor; Fook-Thean Lee; Terrance G Johns; Joan K Heath; Matthias Ernst; Antony W Burgess; Andrew M Scott
Journal:  EJNMMI Res       Date:  2014-05-30       Impact factor: 3.138

3.  Tumor-targeted Dual-modality Imaging to Improve Intraoperative Visualization of Clear Cell Renal Cell Carcinoma: A First in Man Study.

Authors:  Marlène C Hekman; Mark Rijpkema; Constantijn H Muselaers; Egbert Oosterwijk; Christina A Hulsbergen-Van de Kaa; Otto C Boerman; Wim J Oyen; Johan F Langenhuijsen; Peter F Mulders
Journal:  Theranostics       Date:  2018-03-08       Impact factor: 11.556

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.